Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: VolitionRx Limited

Market Cap 11.5M 9.93M 9.15M 8.56M 16.05M 1.09B 16.3M 108M 42.12M 532M 43.14M 42.23M 1.84B P/E Ratio 2026 *
-0.59x
P/E Ratio 2027 * -1x
Enterprise Value 11.5M 9.93M 9.15M 8.56M 16.05M 1.09B 16.3M 108M 42.12M 532M 43.14M 42.23M 1.84B EV / Sales 2026 *
4.7x
EV / Sales 2027 * 2.01x
Free-Float
65.83%
Yield 2026 *
-
Yield 2027 * -
1 day-5.48%
1 week-22.91%
Current month-48.31%
1 month-40.52%
3 months-64.81%
6 months-74.35%
Current year-73.00%
1 week 1.3
Extreme 1.3
1.56
1 month 1.3
Extreme 1.3
3.26
Current year 1.3
Extreme 1.3
7.73
1 year 1.3
Extreme 1.3
18.8
3 years 1.3
Extreme 1.3
35.8
5 years 1.3
Extreme 1.3
82.8
10 years 1.3
Extreme 1.3
136.8
Manager TitleAgeSince
Chief Executive Officer 55 2011-10-05
Director of Finance/CFO 56 2021-01-31
Chief Tech/Sci/R&D Officer 49 2024-03-31
Director TitleAgeSince
Chairman 61 2024-11-05
Director/Board Member 55 2011-10-05
Director/Board Member - 2024-09-29
Date Insider Type Main position Quantity % Market Cap.
03-16Tax

Chief Technology Officer

5,310 0.0039%
03-16Tax

Executive/Senior Manager

5,251 0.0039%
03-16Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-5.48%-22.91%-88.42%-95.27% 12.16M
-0.19%-2.87%+77.33%+76.87% 3.78B
-6.03%+4.14%+69.07%+121.66% 3B
+4.05%-1.16%-34.44%-38.77% 1.86B
+3.03%-3.55%+76.62%-51.94% 1.77B
-2.92%+3.24%+21.99%+176.75% 1.22B
-0.36%-9.66%-16.52%+15.91% 848M
-0.72%-29.91%+107.22% - 780M
-4.41%-0.80%+120.35%-64.81% 769M
+0.66%-3.26%-28.98%-20.41% 535M
Average -1.24%-3.21%+30.42%+13.33% 1.46B
Weighted average by Cap. -0.92%-0.22%+50.99%+47.77%

Financials

2026 *2027 *
Net sales 2.45M 2.11M 1.95M 1.82M 3.42M 233M 3.47M 23.01M 8.97M 113M 9.19M 8.99M 392M 5.73M 4.95M 4.56M 4.27M 8M 545M 8.13M 53.88M 21.01M 265M 21.52M 21.06M 918M
Net income -22.74M -19.64M -18.1M -16.94M -31.74M -2.16B -32.23M -214M -83.3M -1.05B -85.33M -83.51M -3.64B -19.62M -16.94M -15.61M -14.62M -27.39M -1.86B -27.82M -184M -71.89M -908M -73.63M -72.06M -3.14B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
26-06-12 1.380 $ -5.48% 319,831
26-06-11 1.460 $ +5.04% 156,513
26-06-10 1.390 $ +2.21% 230,417
26-06-09 1.360 $ -2.16% 378,815
26-06-08 1.390 $ -22.35% 1,316,888
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.380USD
Average target price
20.21USD
Spread / Average Target
+1,364.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!